Abstract
A characteristic feature of patients suffering from connective tissue diseases such as polymyositis (PM), dermatomyositis, systemic sclerosis (scleroderma, SSc, Scl), systemic lupus erythematosus or overlap syndromes thereof are anti-nuclear antibodies and anti-nucleolar antibodies. Antibodies to the PM/Scl complex, also known as the human exosome complex, belong to the anti-nucleolar antibodies and are mainly found in patients with PM/SSc overlap syndrome and related diseases. Until recently, the detection of anti-PM/Scl antibodies was laborious and relied largely on indirect immunofluorescence and immunodiffusion techniques. With the identification and characterization of the autoantigens, especially PM/Scl-75, PM/Scl-100 and a synthetic peptide (PM1-Alpha) thereof, newly developed assays based on recombinant proteins and peptides have allowed the development of a new generation of anti-PM/Scl tests with high sensitivity and specificity. These novel assays (i.e. ELISA, line immunoassays and protein arrays) enable testing for anti-PM/Scl in modern, automated, multi-parametric assay settings. The present review focuses on recent insights on anti-PM/Scl autoantibodies with special emphasis on clinical, genetic and diagnostic aspects.
| Original language | English |
|---|---|
| Pages (from-to) | 432-437 |
| Number of pages | 6 |
| Journal | Autoimmunity Reviews |
| Volume | 6 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Aug 2007 |
| Externally published | Yes |
Bibliographical note
Copyright:Copyright 2009 Elsevier B.V., All rights reserved.
Keywords
- Autoantibody
- Exosome
- PM/Scl
- Polymyositis
- Systemic sclerosis
